The Latest News and Notes, plus Conversation with Julia Haller, MD

Eyeluminaries

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Julia Haller, MD, about the latest developments in retina, residency training and more.

• Welcome to the Eyeluminaries podcast :01
• Review of episode 17, live from Octane OTF :41
• Bausch + Lomb makes a number of big moves under the new Brent Saunders regime 1:40
• Mark Baum and Harrow Health have also been making a number of acquisitions 3:59
• FDA approves Xdemvy for Demodex blepharitis treatment 5:45
• Former CEO of Johnson & Johnson Alex Gorsky elected lead director of Neurotech’s board 7:47
• John begins new clinical committee for ASCRS, digital 9:32
• Julia Haller, MD introduction 11:30
• ReST Committee update on intraocular inflammation reported in patients who received Syfovre at the American Society of Retina Specialists annual meeting 13:44
• The FDA approved Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Astellas Pharma 14:16
• Novartis is discontinuing the development of GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration 14:36
• How has the latest retina news affected patients and physicians? 14:53
• The development of biosimilars 19:50
• Discussion on pricing of products 21:57
• The evolution and future of residency programs 23:34
• Fun with retina drug names 27:15
• Preview of episode 19 at OSN New York 29:46
• Feedback, questions and guest suggestions at [e-mail] 30:15
• Thanks for listening 30:27

John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.

Julia Haller, MD, is Ophthalmologist-in-Chief and William Tasman, MD Endowed Chair at Wills Eye Hospital and Professor and Chair of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, PA.

We’d love to hear from you! Send your comments/questions to [e-mail]. Follow John Hovanesian on Twitter @DrHovanesian.

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Haller reports being on the board of directors at Bristol Myers Squibb, Opthea and Outlook Therapeutics. She is consultant to Aura Biosciences, Bionic Sight, Lowy Medical Research Institute and Regeneron.